180-Day Exclusivity Decision On Acarbose Illustrates Importance Of ANDA Quality

FDA's decision to deny Cobalt 180-day exclusivity for its ANDA of acarbose (Bayer's diabetes treatment Precose) illustrates the importance for generic firms of submitting high-quality applications